8 results
The current study is being conducted to determine whether long-term dual-antiplatelet therapy with ticagrelor in combination with ASA (recommended daily dose 75-100 mg) is beneficial in patients with history of MI (1-3 years ago) and additional risk…
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
To compare the efficacy of doxycycline 40 mg (Efracea) versus minocycline 100 mg treatment in adult patients with papulopustular rosacea.
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.
To evaluate safety of 3-months versus standard 12-months of DAPT
To investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.